Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,385
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Glucose 5% 50 ml
Disc Medicine
Apnea of prematurity
1 trial -
HEPARIN , NADROPARIN
Disc Medicine
All patients who receive ECMO treatment during the study period in one the participating centers from which (deferred) informed consent is obtained. Patients in whom the ECMO is only used to bridge a procedure like a high risk percutaneous coronary intervention or during surgery are excluded.
1 trial -
Instant MSC Product accompanying Autologous Chondron Transplantation (IMPACT)
Disc Medicine
Symptomatic articular cartilage lesion of the knee (femoral condyles or trochlea)
1 trial -
Insulatard 100 international units/ml suspension for injection in vial., Natriumchloride 0,9% oplossing voor injectie
Disc Medicine
Delirium
1 trial -
Irinotecan HCl-trihydraat Accord 20 mg/ml concentraat voor oplossing voor infusie, Oxaliplatine Fresenius Kabi 5 mg/ml concentraat voor oplossing voor infusie, Folinezuur Sandoz 10 mg/ml, oplossing voor injectie, Fluorouracil Accord 50 mg/ml, oplossing voor injectie of infusie
Disc Medicine
Non-metastatic resectable pancreatic cancer
1 trial -
Irinotecan HCl-trihydraat Fresenius Kabi 20 mg/ml, concentraat voor oplossing voor infusie, Folinezuur Sandoz 10 mg/ml, oplossing voor injectie, Gemcitabine Sandoz 40 mg/ml, concentraat voor oplossing voor infusie, Fluorouracil Accord 50 mg/ml, oplossing voor injectie of infusie, Oxaliplatine Fresenius Kabi 5 mg/ml concentraat voor oplossing voor infusie
Disc Medicine
non-metastatic (borderline) resectable pancreatic cancer
1 trial -
KEYTRUDA 25 mg/mL concentrate for solution for infusion
Disc Medicine
Advanced NSCLC
1 trial -
KEYTRUDA 25 mg/mL concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion
Disc Medicine
Patients with advanced, metastatic NSCLC that have not progressed on a standard of care immunotherapy regimen 6 months after initiation of first line treatment.
1 trial -
KEYTRUDA 25 mg/mL concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.
Disc Medicine
Melanoma
1 trial -
Ketanest-S 25 Multi-dose, oplossing voor injectie 25 mg/ml
Disc Medicine
Non-psychotic therapy resistant unipolar depression
1 trial -
Kyprolis 60 mg powder for solution for infusion, Kyprolis 30 mg powder for solution for infusion, DARZALEX 1800 mg solution for injection, ENDOXAN omhulde tablet, omhulde tabletten, 50 mg, Cesnicabtagene autoleucel, Kyprolis 10 mg powder for solution for infusion, Dexamethason Teva 4 mg, tabletten, Bortezomib Accord 3.5 mg powder for solution for injection, Empliciti 300 mg powder for concentrate for solution for infusion., Dexamethason Activase 2 mg tabletten, Pomalidomide Accord 4 mg hard capsules, Emplic
Disc Medicine
relapsed/refractory multiple myeloma
1 trial -
LEUPRORELIN
Disc Medicine
polycystic liver disease
1 trial -
LIOTHYRONINE SODIUM , LEVOTHYROXINE SODIUM , Placebo tablets are white, round, biconvex tablets. The tablets contain no active pharmaceutical ingredient (API), but are manufactured following the manufacturing process of the liothyronine tablets presented in the IMPD for liotyronine 2, 2.5, 3.75, and 5 Β΅g
Disc Medicine
Hypothyroidism Triiodothyronine Quality of Life Persistant complaints
1 trial -
Lactose monohydrate, Melatonine Tiofarma 5 mg tabletten
Disc Medicine
Chronic low back pain
1 trial -
Leflunomide Mylan 10 mg, filmomhulde tabletten, PLACEBO
Disc Medicine
polymyalgia rheumatica
1 trial -
METFORMIN, COLCHICINE
Disc Medicine
PASC: post-acute sequelae of SARS-CoV-2 infection
1 trial -
METFORMIN, COLCHICINE, MINOCYCLINE, Placebo tablets are identical to active minocycline tablets and will be relabelled identical to the study drug. Placebo tablets will have the same composition, except for the active substance. (microcrystalline cellulose, magnesium stearate).
Disc Medicine
PASC: post-acute sequelae of SARS-CoV-2 infection
1 trial -
Modiodal 100 mg tabletten, PLACEBO
Disc Medicine
Inflammatory bowel disease, Fatigue
1 trial -
NaCl 0,9 % B. Braun, solution injectable, Depo-Medrone 40 mg/ml Suspension for Injection.
Disc Medicine
Cluster headache
1 trial -
OPDIVO 10 mg/mL concentrate for solution for infusion.
Disc Medicine
oesophageal cancer
1 trial -
OPDIVO 10 mg/mL concentrate for solution for infusion., YERVOY 5 mg/ml concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion
Disc Medicine
Melanoma
1 trial -
PLASMA, Omniplasma 45-70 mg/ml oplossing voor infusie
Disc Medicine
Coagulation in pediatric cardiac surgery
1 trial -
PROGRAF 1 mg capsule, Envarsus 0.75 mg prolonged-release tablets
Disc Medicine
lung transplantation
1 trial -
Placebo
Disc Medicine
Erythropoietic Protoporphyria (EPP)
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources